Co-Founder of Array BioPharma to Lead New Korean Out-Sourcing Chemistry Company
BOULDER, Colo., Dec. 13 /PRNewswire-FirstCall/ -- Array BioPharma Inc. (Nasdaq: ARRY) today announced that one of its Founders, Anthony Piscopio, Ph.D., is leaving the Company at the end of the year to pursue a new opportunity as Chairman and Chief Executive Officer of Chemizon, a growing chemistry-based out-sourcing company based in South Korea. Dr. Piscopio served as Vice President of Chemistry and Director of Process Research and Development at Array since its founding in 1998.
"Tony was instrumental in building the Array Discovery Platform into one of the premier small molecule drug discovery capabilities in the biotech industry," said Robert E. Conway, Chief Executive Officer, Array BioPharma. "Thanks to his efforts, Array has a world-class process R&D team to drive our products into clinical development. We are grateful to Tony for his vision and dedication on behalf of the organization over the past seven years."
Dr. Piscopio founded Array, along with Kevin Koch, Ph.D., David Snitman, Ph.D. and K.C. Nicolaou, Ph.D., in 1998. Since that time, the Company has grown from 25 to 270 employees and is a recognized leader in small molecule drug discovery and development. Tony led the building of the process research and development team, comprised of over 30 scientists in four groups: Process Research, Analytical Development, Formulations and cGMP Manufacturing.
About Array BioPharma:
Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat life threatening and debilitating diseases. Our proprietary drug development pipeline is focused on the treatment of cancer and inflammatory disease and includes clinical candidates that are designed to regulate therapeutically important targets. In addition, leading pharmaceutical and biotechnology companies collaborate with Array to discover and develop drug candidates across a broad range of therapeutic areas. For more information on Array, please go to www.arraybiopharma.com.
SOURCE Array BioPharma Inc.
CONTACT: Tricia Haugeto of Array BioPharma Inc., +1-303-386-1193, firstname.lastname@example.org
Web site: http://www.arraybiopharma.com